Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: Results from an international surveillance study

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL.3, 2011, Pages

  Jones, Ronald N ^a   Farrell, David J ^a   Mendes, Rodrigo E ^a   Sader, Helio S ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Cephalosporins; Europe; MDR S. Pneumoniae; MRSA; Surveillance; USA

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; ERTAPENEM; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SURVEILLANCE; DRUG POTENCY; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIA; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; UNITED STATES;

EID: 79954578994     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr101     Document Type: Article

References (59)

1. Citron DM, Tyrrell KL, Merriam V et al. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob Agents Chemother 2010; 54: 1627-32.
2. Fenoll A, Aguilar L, Robledo O et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother 2008; 52: 4209-10.
3. Ge Y, Biek D, Talbot GH et al. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52: 3398-407.
4. Iizawa Y, Nagai J, Ishikawa T et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004; 10: 146-56.
5. Ikeda Y, Ban J, Ishikawa T et al. Stability and stabilization studies of TAK-599 (ceftaroline fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant Staphylococcus aureus cephalosporin T-91825. Chem Pharm Bull 2008; 56: 1406-11.
6. Ishikawa T, Matsunaga N, Tawada H et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003; 11: 2427-37.
7. Jacobs MR, Good CE, Windau AR et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010; 54: 2716-9.
8. Jones RN, Fritsche TR, Ge Y et al. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005; 56: 1047-52.
9. Jones RN, Mendes RE, Sader HS. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother 2010; Suppl 4: iv17-31.
10. McGee L, Biek D, Ge Y et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009; 53: 552-6.
11. Morrissey I, Ge Y, Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 2009; 33: 515-9.
12. Patel SN, Pillai DR, Pong-Porter S et al. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J Antimicrob Chemother 2009; 64: 659-60.
13. Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 1153-5.
14. Sader HS, Fritsche TR, Kaniga K et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005; 49: 3501-12.
15. Zhanel GG, Sniezek G, Schweizer F et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs 2009; 69: 809-31.
16. Kanafani ZA, Corey GR. Ceftaroline: a cephalosporin with expanded Gram-positive activity. Future Microbiol 2009; 4: 25-33.
17. Mushtaq S, Livermore DM. AmpC induction by ceftaroline. J Antimicrob Chemother 2010; 65: 586-8.
18. Mushtaq S, Warner M, Ge Y et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60: 300-11.
19. Barton E, MacGowan A. Future treatment options for Gram-positive infections-looking ahead. Clin Microbiol Infect 2009; 15 Suppl 6: 17-25.
20. Bazan JA, Martin SI, Kaye KM. Newer b-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime. Infect Dis Clin North Am 2009; 23: 983-96.
21. Kollef MH. New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc 2009; 11: 282-6.
22. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
23. Spellberg B, Fleming TR, Gilbert DN. Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia. Clin Infect Dis 2008; 47 Suppl 3: S105-7.
24. FDA. Guidance for Industry. Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment. March 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm123686.pdf (26 July 2010, date last accessed).
25. Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: Implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010; 36: 197-204.
26. Jacqueline C, Caillon J, Le Mabecque V et al. In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin. Antimicrob Agents Chemother 2009; 53: 5300-2.
27. Jacqueline C, Caillon J, Le Mabecque V et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007; 51: 3397-400.
28. Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009; 53: 4712-7.
29. Corey GR, Wilcox MH, Talbot GH et al. on behalf of the CANVAS 1 Investigators. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv41-51.
30. Talbot GH, Thye D, Das A et al. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007; 51: 3612-6.
31. Wilcox MH, Corey GR, Talbot GH et al. on behalf of the CANVAS 2 Investigators. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv53-65.
32. Eckburg P, Friedland HD, Lee J et al. FOCUS 1 and 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP). In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract L1-345a. American Society for Microbiology, Washington, DC, USA.
33. Echols RM, Tillotson GS, Song JX et al. Clinical trial design for mild-to-moderate community-acquired pneumonia-an industry perspective. Clin Infect Dis 2008; 47 Suppl 3: S166-75.
34. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51 Suppl 1: S81-7.
35. Jones RN, Sader HS, Moet GJ et al. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009). Diagn Microbiol Infect Dis 2010; 68: 334-6.
36. Gertz RE Jr, Li Z, Pimenta FC et al. Active Bacterial Core Surveillance Team. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis 2010; 201: 770-5.
37. Mera R, Miller LA, Fritsche TR et al. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist 2008; 14: 101-7.
38. Moore MR, Gertz RE Jr, Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008; 197: 1016-27.
39. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009; 48: 1596-600.
40. CDC. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 325-9.
41. Gillet Y, Vanhems P, LinaGet al. Factors predictingmortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007; 45: 315-21.
42. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Eighth Edition: Approved Standard M07-A8. CLSI, Wayne, PA, USA, 2009.
43. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. CLSI, Wayne, PA, USA, 2010.
44. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 1.1, April 2010. http://www.eucast.org/clinical_breakpoints/ (10 June 2010, date last accessed).
45. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria: Approved Guideline M45-A. CLSI, Wayne, PA, USA, 2006.
46. Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006; 50: 1376-83.
47. Ge Y, Maynard D, Rickert DE. Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection. Antimicrob Agents Chemother 2010; 54: 912-4.
48. Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009; 53: 1271-4.
49. Mendes RE, Sader HS, Deshpande LM et al. Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid. J Clin Microbiol 2010; 48: 568-74.
50. Milheiriço C, Oliveira DC, de Lencastre H. Update to the multiplex PCR strategy for assignment of mec element types in Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 3374-7.
51. Weller TMA. The distribution of mecA, mecR1 and mecI and sequence analysis of mecI and the mec promoter region in staphylococci expressing resistance to methicillin. J Antimicrob Chemother 1999; 43: 15-22.
52. Farrell DJ, Patel SN, McGeer A et al. Activity of ceftaroline (CPT) against recent Streptococcus pneumoniae (SP) isolates from the Canadian Bacterial Surveillance Network (CBSN). In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract C2-1391. American Society for Microbiology, Washington, DC, USA.
53. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother 2010; 65: 713-6.
54. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other b-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2010; 54: 1670-7.
55. Panagiotidis G, Bäckström T, Asker-Hagelberg C et al. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother 2010; 54: 1811-4.
56. Vidaillac C, Leonard SN, Sader HS et al. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 2360-6.
57. Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftaroline against Gram-positive organisms. Antimicrob Agents Chemother 2009; 53: 4537-9.
58. Jones RN, Deshpande LM, Mutnick AH et al. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002; 50: 915-32.
59. Christensen KL, Holman RC, Steiner CA et al. Infectious disease hospitalizations in the United States. Clin Infect Dis 2009; 49: 1025-35.